Equities

Establishment Labs Holdings Inc

Establishment Labs Holdings Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)43.96
  • Today's Change1.63 / 3.85%
  • Shares traded2.00
  • 1 Year change-13.16%
  • Beta1.2085
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.

  • Revenue in USD (TTM)151.35m
  • Net income in USD-83.20m
  • Incorporated2013
  • Employees857.00
  • Location
    Establishment Labs Holdings IncBuilding B15 And 25 Coyol Free ZoneALAJUELA 20101Costa RicaCRI
  • Phone+506 24342400
  • Websitehttps://establishmentlabs.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Alphatec Holdings Inc540.28m-180.91m872.26m839.00--51.90--1.61-1.34-1.344.000.28470.77361.137.30643,959.50-25.90-30.97-33.24-39.4769.4466.02-33.48-46.221.21-4.590.9273--37.4539.38-23.36--67.92--
Embecta Corp1.12bn69.70m906.50m2.20k13.02--8.370.81021.211.2119.36-13.240.88822.1111.60508,590.905.53--7.91--66.42--6.23--1.612.061.88---0.7703---68.52------
Bioventus Inc536.89m-41.96m938.48m1.03k--6.22--1.75-0.6595-0.65958.481.860.65911.954.18553,495.90-6.70-5.52-9.65-7.2766.5368.25-10.16-10.940.9561.080.6697--0.04459.936.91--23.51--
Figs Inc550.80m18.68m961.94m354.0054.722.3943.121.750.10290.10293.042.351.181.2358.021,555,932.003.99--4.65--68.02--3.39--3.89--0.00--7.87--6.85------
Artivion Inc376.97m-8.32m1.05bn1.50k--3.5670.162.79-0.2076-0.20769.117.060.4811.675.44251,316.00-1.07-2.20-1.15-2.3664.6365.51-2.22-5.344.041.070.5177--12.826.14-60.09--5.13--
Avanos Medical Inc682.40m7.00m1.13bn3.77k161.120.927721.731.660.15320.167114.7126.620.41051.935.20180,960.000.4211-0.65270.4737-0.733855.8254.451.03-1.601.497.060.1253---1.580.6357-146.05---18.37--
Pulse Biosciences Inc0.00-44.02m1.15bn56.00--38.36-----0.7916-0.79160.000.48830.00----0.00-76.43-93.21-84.97-104.99-------12,332.25----0.00---100.00--27.85---15.20--
BioLife Solutions Inc121.17m-53.87m1.19bn409.00--3.69--9.79-1.21-1.642.696.970.29991.995.39296,254.30-13.33-13.76-14.60-15.0441.2736.76-44.46-42.991.81-5.980.0651---11.4348.6552.49--86.35--
Establishment Labs Holdings Inc151.35m-83.20m1.23bn857.00--27.28--8.12-3.11-3.115.621.610.53070.85252.72166,685.00-29.17-33.22-34.29-41.1266.0464.73-54.97-43.192.91-20.680.8114--2.1321.96-4.38--69.16--
Owens & Minor, Inc.10.53bn-42.44m1.24bn13.70k--1.445.150.1174-0.5532-0.5532137.9811.171.996.9515.78768,728.30-0.80141.32-1.252.0720.7816.48-0.4030.56140.51412.110.70760.7983.801.87-284.47--25.91--
Inmode Ltd416.63m149.20m1.35bn581.0010.241.959.033.251.731.734.849.090.52281.6211.78717,084.3018.7231.3220.7935.6482.2784.4635.8139.658.09--0.000.008.3237.4922.5454.6513.10--
Integra Lifesciences Holdings Corp1.57bn23.65m1.36bn3.95k59.000.88348.890.86520.29610.296120.0219.770.3991.555.81396,986.100.60233.330.66183.6861.5463.671.517.992.105.880.54330.00-1.030.9219-62.482.19-2.97--
AtriCure Inc429.95m-40.12m1.40bn1.20k--3.04--3.26-0.8606-0.86069.229.490.72171.688.27358,294.20-6.73-3.72-7.58-4.1074.8474.36-9.33-7.642.93-11.790.12--20.8414.6434.49--46.56--
Adapthealth Corp3.26bn-692.75m1.52bn10.70k--1.01--0.466-5.17-5.1724.2911.140.671422.228.12304,741.80-14.15-4.34-15.89-4.8918.6318.28-21.07-6.470.94382.170.5866--7.73---1,169.99------
STAAR Surgical Co332.94m16.61m1.55bn1.06k94.333.8070.384.670.3350.3356.758.320.69842.133.54315,286.003.496.773.997.9079.2476.894.999.165.21--0.00030.0013.3721.07-46.1833.8551.95--
Data as of Sep 19 2024. Currency figures normalised to Establishment Labs Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

56.44%Per cent of shares held by top holders
HolderShares% Held
JW Asset Management LLCas of 30 Jun 20243.19m11.43%
RTW Investments LPas of 30 Jun 20242.68m9.58%
Nantahala Capital Management LLCas of 30 Jun 20242.51m8.99%
Brown Advisory LLCas of 30 Jun 20242.16m7.73%
Findell Capital Management LLCas of 30 Jun 20241.11m3.98%
Capital Research & Management Co. (Global Investors)as of 30 Jun 20241.00m3.58%
TD Securities (USA) LLCas of 30 Jun 2024939.95k3.36%
JPMorgan Investment Management, Inc.as of 30 Jun 2024799.83k2.86%
Rice, Hall, James & Associates LLCas of 30 Jun 2024716.34k2.56%
Morgan Stanley & Co. LLCas of 30 Jun 2024661.51k2.37%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.